Practice
Featured experience
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
SouthState $2 billion acquisition of Independent Bank Group
We are advising SouthState on the acquisition
Tailwind Capital investment in GrayMatter Systems
We are advising Tailwind Capital on the investment
Uniti Group merger with Windstream
We are advising Uniti Group on the transaction
Svitzer Group demerger and Copenhagen listing
We advised A.P. Moller – Maersk and Svitzer Group on the demerger and commencement of trading in shares of Svitzer Group
UMB Financial $2 billion acquisition of Heartland Financial
We are advising UMB on the acquisition and a $201.6 million stock offering
AssetMark $2.7 billion acquisition by GTCR
We are advising AssetMark on the transaction
Barratt Developments £2.52 billion all-share offer for Redrow
We are advising UBS as financial adviser and sponsor to Barratt Developments on the transaction
Perella Weinberg sale of Agility to Cerity Partners
We are advising Perella Weinberg on the transaction
Nuvei $6.3 billion going-private acquisition
We are advising Nuvei on the transaction
AnHeart Therapeutics acquisition by Nuvation Bio
We are advising AnHeart Therapeutics on the acquisition